Exelixis Surges After Cabometyx Granted Priority Review, Meets Endpoint In Trial
October 16, 2017 at 13:50 PM EDT
Shares of Exelixis jumped in early trading after the biopharmaceutical company said it received priority review from the U.S. Food and Drug Administration for a treatment for advanced renal cell carcinoma.
